-
Specialties
- Invasive Mucinous Adenocarcinoma of the Lung
- Lung Cancer
- Medical Oncology
- Thoracic Oncology
Board Certification
American Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Medical Oncology)National Board of Medical ExaminersPatient Rating
5.0 /5( out of 14 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.July 21, 2024HUNTSMAN CANCER CENTERDr. Gumbleton took his time in explaining things to us; if there was anything that wasn't understood, he explained it a second time. He provided hand-written charts to help. He 'prodded' us for any questions that we perhaps hadn't thought of. All with a very professional attitude but so very friendly and kind. This is a difficult position to be in and he made it somewhat less stressful. The way he handled things and worked with us was very much appreciated. He has the extra-special personality that is necessary in the type of work he does. I would recommend Dr. Gumbleton to anyone, anywhere, with absolutely no qualms. I look forward to continuing to deal with him.
June 09, 2024HUNTSMAN CANCER CENTERThe only shortcoming I experienced was that I had, at times, difficulty understanding some of what he was saying due mostly to my very poor hearing
April 08, 2024HUNTSMAN CANCER CENTERDr. Gumbleton is a great Doctor! he cares about me and my family !!
April 07, 2024HUNTSMAN CANCER CENTERDr Gumbelton listened very well, told me what he was thinking, not holding back, and I had an excellent time with him, and I highly recommend him. I'm glad that I am under his care. I could not be more satisfied than I am now.
March 18, 2024HUNTSMAN CANCER CENTERDr Matthew N Gumbleton is one of the greatest doctors I've have seen by through my treatments he is so good in listening to every word you say and always has a answer to your questions or will give you his best advice to any issues you may have I feel so save having him as my doctor
March 10, 2024HUNTSMAN CANCER CENTERDr Gumbleton is caring and compassionate. He goes to great lengths to help you understand what is happening, what treatment options are and letting you make your decisions. Excellent Excellent care.
February 22, 2024HUNTSMAN CANCER CENTERI made the best decision in getting a second opinion and switching doctors with Dr. Gumbleton he made me feel so safe and caring as if I was a family and I'm looking forward to fighting this battle of my cancer with Dr. Gumbleton and staff at my side because I have all the confidence we can get through this together.
January 30, 2024HUNTSMAN CANCER CENTERDr. Gumbleton is the best !!
December 26, 2023HUNTSMAN CANCER CENTERI feel Dr. Gumbleton is a very knowledgeable professional.
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Primary Academic Divisions Oncology
Board Certification American Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Medical Oncology)National Board of Medical ExaminersEducation history
Postdoctoral Fellowship Huntsman Cancer Institute Postdoctoral Research Fellow Hematology & Medical Oncology - Huntsman Cancer Institute Fellow Residency Internal Medicine - University of Utah School of Medicine Resident Internal Medicine - University of Utah School of Medicine Intern/Resident Professional Medical Microbiology & Immunology - SUNY Upstate Medical University Norton College of Medicine M.D., Ph.D. Microbiology & Immunology - Kalamazoo College B.S. Selected Publications
Journal Article
- Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta S (2023). A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC Res Notes, 16(1), 16. (Read full article)
- Gumbleton M, Sudan R, Fernandes S, Engelman RW, Russo CM, Chisholm JD, Kerr WG (2017). Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival. Sci Signal, 10(500). (Read full article)
- Iyer S, Brooks R, Gumbleton M, Kerr WG (2015). SHIP1-expressing mesenchymal stem cells regulate hematopoietic stem cell homeostasis and lineage commitment during aging. Stem Cells Dev, 24(9), 1073-81. (Read full article)
- Gumbleton M, Vivier E, Kerr WG (2015). SHIP1 intrinsically regulates NK cell signaling and education, resulting in tolerance of an MHC class I-mismatched bone marrow graft in mice. J Immunol, 194(6), 2847-54. (Read full article)
- Fernandes S, Brooks R, Gumbleton M, Park MY, Russo CM, Howard KT, Chisholm JD, Kerr WG (2015). SHIPi Enhances Autologous and Allogeneic Hematolymphoid Stem Cell Transplantation. EBioMedicine, 2(3), 205-213. (Read full article)
- Gumbleton M, Kerr WG (2013). Role of inositol phospholipid signaling in natural killer cell biology. Front Immunol, 4, 47. (Read full article)
- Fuhler GM, Brooks R, Toms B, Iyer S, Gengo EA, Park MY, Gumbleton M, Viernes DR, Chisholm JD, Kerr WG (2012). Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol Med, 18(1), 65-75. (Read full article)
- Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova JL (2011). Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science, 332(6025), 65-8. (Read full article)
Patent
- William K, Gumbleton M (2020). Ship inhibition to induce activation of natural killer cells. U.S. Patent No. WO2015195812. Washington, D.C.:U.S. Patent and Trademark Office.